Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. - Wikidata - awgldk - TriplyDB

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

http://www.wikidata.org/entity/Q34618537

about

Gemcitabine-based chemotherapy for advanced biliary tract carcinomas Current status of transarterial radioembolization The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly Hepatobiliary Tumors: Update on Diagnosis and Management Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review Gallbladder Cancer in the 21st Century.Current status of endoscopic biliary drainage for unresectable malignant hilar biliary strictures Is There Any Evidence for a Role of Local Treatment in Cholangiocarcinoma?Targeted Therapy in Biliary Tract Cancers Advances in systemic therapy for advanced pancreatobiliary malignancies Current diagnostic and management options in perihilar cholangiocarcinoma Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma Primary sclerosing cholangitis: diagnosis and treatment Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies Cholangiocarcinoma Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies Optimum chemotherapy for the management of advanced biliary tract cancer Cancer concepts and principles: primer for the interventional oncologist-part II Progression of targeted therapy in advanced cholangiocarcinoma Ampullary cancer: an overview The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma Cancer and liver cirrhosis: implications on prognosis and management Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review Cholangiocarcinoma: Current Knowledge and New Developments Current Status on Cholangiocarcinoma and Gallbladder Cancer DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract Photodynamic therapy for cholangiocarcinoma Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers Management of perihilar cholangiocarcinoma in the era of multimodal therapy Classification, diagnosis, and management of cholangiocarcinoma Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution.Surgical options for intrahepatic cholangiocarcinoma.Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Update on the Diagnosis and Treatment of Cholangiocarcinoma.

P2860

Q24187573-B8101B3E-D75F-438C-9C3B-F36F0BEB3E9F Q26744307-23F55FA4-3587-4F96-8476-9B206693FD75 Q26751224-A733ACE6-DD2E-4A38-AF4B-4A5B535EC524 Q26771399-2D9066D6-872E-4A4E-8FF1-A5AAD3C0F521 Q26775654-A42EDCD3-E574-4F75-9448-EB231B522142 Q26781036-B709134D-BEDD-4413-89D6-043F23B1DC70 Q26784174-8EF9E0DA-52A2-4111-9FEF-CA7BE096D1B4 Q26795776-9D481AE6-C7F4-4AEF-BFE6-81F99583D73C Q26796522-296B50CC-FE13-49C7-B1E3-8182D6E4DFBE Q26798443-0FC38AD7-8D17-462C-9FDA-8880B767CC21 Q26822703-938C8319-7C78-4394-901E-A1B8BFDA8E32 Q26822808-95DEAAD7-FD4C-4EA8-BCD5-57D03BEA479D Q26824969-16937246-FC92-48FB-A367-CB67F2B2C3E4 Q26829216-E3CE27C2-231F-44AF-B322-DBD4C2FC3718 Q26852049-353CABD9-C200-4A2A-8DD4-AEBFFBB47845 Q27001694-5ED850BE-7181-45A8-A4C0-6423F2E2B249 Q27002547-69BC7E36-CDF9-4648-82D2-F458888F3649 Q27010873-21A62565-8146-4147-A290-ED0A41A331AF Q27010961-26B2DA57-840D-4990-AE65-71FCF70F1FAA Q27016150-E02F7522-B828-49BB-8132-7906A7079EF0 Q27023881-F395FEAC-4BDC-468A-8A2F-74B99750E118 Q27340125-5AC0B02C-83A7-4365-9A65-C96D547398DD Q27852856-B1AF39BD-EC54-4B5C-82D1-04DEA096D863 Q28068579-53957DC1-A3EC-485D-BD36-5CBAD072FF45 Q28073195-3F4F7ACD-24C0-41E1-A9F0-5F8EFB19282E Q28074145-B5AC306F-A4D1-4231-9245-52ABEB3F7A3D Q28075370-3C44EB13-2457-4103-BADC-9629ECC0486F Q28076098-4882B53D-63E1-404D-A106-46E5CBBC8ECD Q28077797-4A3F2303-24CB-4522-B25F-DF9D676A0EB0 Q28109676-D0F09253-0F24-4872-905F-AE181E008DB6 Q28252343-DE546B73-1A14-40D2-A928-3ABFAD279486 Q28254804-F60DF69F-FD4C-4B6B-BE3D-465C3DE6A0C1 Q28273788-6969CC08-20D5-4CA3-93A6-18A1BC05C346 Q28275153-61A8F4C7-AA20-4096-BFCF-DE1312F3314D Q28533753-1CA4556A-407D-4884-AE45-4AE00F5A3DF3 Q28550991-46D8C09A-12E2-4673-912D-BD1A3FCBD37F Q30148661-3569F6BD-5258-4F47-8CFC-E93E1DB94D8F Q30234462-AB22B976-7B0C-4BB8-AE05-6327CF06A59E Q30234532-AFCB5367-EEF6-4EDA-B50D-5C0E993C133E Q30238895-48494734-6C37-4159-87A5-A5BE01E9DADC

P2860

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

http://www.wikidata.org/entity/Q34618537

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@ast

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@en

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@nl

type

label

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@ast

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@en

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@nl

prefLabel

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@ast

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@en

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@nl

P1433

Q34618537-F937A3AD-BA55-4408-AFA7-3BC8660BD124

P1476

Q34618537-1F833242-606E-4393-BEEF-8488A5475C0A

P2093

Q34618537-04ED08EA-DD21-4428-8304-FE721E70F229

Q34618537-31709E0D-AF7F-41D2-8FAE-FF64712A2761

Q34618537-65AAC328-651C-4B67-BE33-FD61710D41CF

Q34618537-7440C538-BF2A-41EC-9A44-F4F17137BDB6

Q34618537-7BBDDE0B-2505-456B-8988-0005AF497882

Q34618537-7E1D2690-1F6A-49BF-8BCB-C5625B3F0D52

Q34618537-7EE4C850-9374-4C9B-860B-363282F232C8

Q34618537-898A20A8-47CC-48F5-82A6-1676CBAF8CBE

Q34618537-92534A5B-BBAF-4903-AE57-5D8204B51814

Q34618537-AED5B32F-6095-4459-AD71-012AB0638971

P304

Q34618537-0E2127FB-A635-4B16-9FA2-5300CCA3023D

P31

Q34618537-BCC62FDD-70C3-433E-950A-0937016D87D7

P356

Q34618537-31B421F1-F670-453D-896D-0B8447D1ABA3

P407

Q34618537-16C65943-BAE5-4295-AFCF-2C42DF8C2107

P433

Q34618537-7F95A2D8-CE4D-4A90-BB95-495A03692690

P478

Q34618537-8286C15C-D530-4D8A-9C4F-C920A3F83747

P50

Q34618537-3DD5E688-768E-407D-AC58-36BEC4F51D56

P577

Q34618537-FB6FFD44-E42C-4B58-A02E-B40609D356A0

P698

Q34618537-436474A4-EE73-4363-85BA-9FEA20F80CC8

P356

P1433

The New England Journal of Medicine

P1476

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

@en

P2093

ABC-02 Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Alan Anthoney

http://www.w3.org/2001/XMLSchema#string

Anthony Maraveyas

http://www.w3.org/2001/XMLSchema#string

Daniel H Palmer

http://www.w3.org/2001/XMLSchema#string

Harpreet Wasan

http://www.w3.org/2001/XMLSchema#string

John Bridgewater

http://www.w3.org/2001/XMLSchema#string

Juan Valle

http://www.w3.org/2001/XMLSchema#string

Michael Roughton

http://www.w3.org/2001/XMLSchema#string

Sharon Hughes

http://www.w3.org/2001/XMLSchema#string

Srinivasan Madhusudan

http://www.w3.org/2001/XMLSchema#string

P304

1273-1281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0908721

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20375404

http://www.w3.org/2001/XMLSchema#string